DaVita Inc
TRL
Company Profile
Business description
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Contact
2000 16th Street
DenverCO80202
USAT: +1 720 631-2100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
78,000
Stocks News & Analysis
stocks
There are 3 good reasons to buy this US dividend stock today
It’s a dividend aristocrat with a healthy yield that looks significantly undervalued even after its recent rally.
stocks
Strategic reset for ASX listed share
The global search for a new CEO is over, ending investor concern about leadership uncertainty.
stocks
ASX listed bank overvalued after shares surge
Investors were pleased with results but our fair value estimate is unchanged.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.80 | 5.80 | -0.06% |
| CAC 40 | 8,316.50 | 4.76 | 0.06% |
| DAX 40 | 24,800.91 | 113.97 | -0.46% |
| Dow JONES (US) | 49,497.29 | 45.31 | 0.09% |
| FTSE 100 | 10,473.69 | 27.34 | 0.26% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,806.41 | 135.56 | -0.24% |
| NZX 50 Index | 13,128.14 | 10.23 | 0.08% |
| S&P 500 | 6,840.79 | 8.03 | 0.12% |
| S&P/ASX 200 | 8,937.10 | 8.30 | -0.09% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |